Cellular engineering startup developing affordable bispecific CAR-T and gene therapies.
| Date | Round | Amount |
|---|---|---|
| May 2026 | Funding round Cellogen Therapeutics raised ₹20 Cr (~$2M) from Kotak Life Sciences Fund I to advance its CAR-T clinical programs. | $2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.